SG Americas Securities LLC Boosts Stake in Urogen Pharma $URGN

SG Americas Securities LLC raised its position in shares of Urogen Pharma (NASDAQ:URGN) by 20.3% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,657,846 shares of the company’s stock after buying an additional 280,199 shares during the quarter. SG Americas Securities LLC owned about 3.41% of Urogen Pharma worth $29,808,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Urogen Pharma by 27.2% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,275 shares of the company’s stock valued at $53,000 after acquiring an additional 486 shares during the last quarter. Russell Investments Group Ltd. increased its position in Urogen Pharma by 1,594.4% in the third quarter. Russell Investments Group Ltd. now owns 3,321 shares of the company’s stock worth $66,000 after purchasing an additional 3,125 shares during the last quarter. Osaic Holdings Inc. raised its stake in Urogen Pharma by 491.2% during the second quarter. Osaic Holdings Inc. now owns 3,695 shares of the company’s stock valued at $50,000 after purchasing an additional 3,070 shares in the last quarter. Tower Research Capital LLC TRC raised its stake in Urogen Pharma by 422.0% during the second quarter. Tower Research Capital LLC TRC now owns 6,891 shares of the company’s stock valued at $94,000 after purchasing an additional 5,571 shares in the last quarter. Finally, ProShare Advisors LLC bought a new position in Urogen Pharma during the fourth quarter valued at $206,000. Hedge funds and other institutional investors own 91.29% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on URGN. Jefferies Financial Group upgraded shares of Urogen Pharma to a “strong-buy” rating in a report on Friday, April 24th. HC Wainwright reaffirmed a “buy” rating and issued a $45.00 price target on shares of Urogen Pharma in a report on Wednesday, June 3rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Urogen Pharma in a research report on Monday, April 20th. Oppenheimer reissued an “outperform” rating on shares of Urogen Pharma in a research note on Tuesday, June 2nd. Finally, LADENBURG THALM/SH SH began coverage on Urogen Pharma in a research report on Monday, May 11th. They set a “buy” rating and a $43.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $39.50.

Urogen Pharma Stock Up 0.5%

URGN opened at $35.15 on Wednesday. The business has a fifty day moving average of $27.67 and a 200 day moving average of $23.12. Urogen Pharma has a 52-week low of $12.73 and a 52-week high of $35.58. The stock has a market cap of $1.71 billion, a P/E ratio of -12.78 and a beta of 1.59.

Urogen Pharma (NASDAQ:URGN) last released its earnings results on Thursday, May 7th. The company reported ($0.47) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.01. The business had revenue of $50.96 million during the quarter, compared to analysts’ expectations of $44.83 million. Equities analysts anticipate that Urogen Pharma will post -0.98 EPS for the current fiscal year.

Insider Activity at Urogen Pharma

In other news, insider Mark Schoenberg sold 5,222 shares of the company’s stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $27.30, for a total value of $142,560.60. Following the transaction, the insider directly owned 139,763 shares in the company, valued at approximately $3,815,529.90. This represents a 3.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 4.80% of the company’s stock.

About Urogen Pharma

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.